Indalo Therapeutics is a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Our lead drug candidate, IDL-2965, began human clinical trials in early 2019. IDL-2965 provides potent antifibrotic efficacy at low once-daily oral doses across multiple animal models of disease in vital organ systems, including liver, lung, and kidney. Our innovative approach builds upon a solid foundation that includes: - A history of scientific and business achievement: Our R&D leadership team was responsible for the development and approval of Esbriet® for IPF at InterMune. - A legacy of deep target knowledge: Our founding scientists have decades of experience in the design, characterization, and development of integrin antagonists. - Marquee investors: Atlas Venture and F-Prime have an unparalleled track record of fostering innovation.